Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

Abstract: The present invention relates to an isolated antibody, which selectively binds to CLEC14A, wherein said antibody (a) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises: (i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO. 105, preferably of SEQ ID NO: 2 or 42; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO. 106, preferably of SEQ ID NO: 3 or 43; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO. 107, preferably of SEQ ID NO: 4 or 44; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO. 108, preferably of SEQ ID NO: 6 or 46; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO. 109, preferably of SEQ ID NO: 7 or 47; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO.

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

Abstract: The invention provides a portion of multimerin 2 (MMRN2) or a variant thereof, that inhibits the interaction between CLEC14A and MMRN2, in addition to a portion of MMRN2 or a variant thereof, that inhibits the interaction between CD93 and MMRN2. The invention provides compounds comprising said portions and either a cytotoxic moiety or a detectable moiety.

Abstract: The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C-type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.

Abstract: The present invention relates to an isolated antibody, which selectively binds to CLEC14A, wherein said antibody (a) comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs, wherein said heavy chain variable region comprises:(i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO. 105, preferably of SEQ ID NO: 2 or 42; (ii) a VH CDR2 that has the amino acid sequence of SEQ ID NO. 106, preferably of SEQ ID NO: 3 or 43; and/or (iii) a VH CDR3 that has the amino acid sequence of SEQ ID NO. 107, preferably of SEQ ID NO: 4 or 44; and/or wherein said light chain variable region comprises: (iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO. 108, preferably of SEQ ID NO: 6 or 46; (v) a VL CDR2 that has the amino acid sequence of SEQ ID NO. 109, preferably of SEQ ID NO: 7 or 47; and/or (vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO.

Abstract: The invention provides a method of inhibiting angiogenes—is in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMNR2.

Abstract: The present invention provides a composition for provoking an immune response in a patient to an autoantigen target, the composition comprising the target conjugated a carrier polypeptide.

Abstract: A method of inhibiting tumor angiogenesis in an individual, the method comprising administering to the individual an inhibitor of CLEC14A. The inhibitor may be an antibody, an siRNA molecule, an antisense molecule, or a ribozyme.

Abstract: A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. An antibody that has the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or the amino acid sequences i) to vi). i) S A S S S V S Y M Y ii) L T S N L A S iii) Q Q W S S N P L T iv) D Y N L N v) V I N P N Y G T T S Y N Q K F K G vi) G R D Y F G Y. A method of inhibiting angiogenesis in an individual in need thereof comprising administering the extracellular domain (residues 1-467) of MR, or a fragment thereof that inhibits angiogenesis, to the individual. A method of inhibiting endothelial cell migration and/or proliferation comprising administering the extracellular domain of MR, or a fragment thereof that inhibits endothelial cell migration and/or proliferation.

Abstract: A method of inhibiting tumour angiogenesis in an individual, the method comprising administering to the individual an inhibitor of CLEC14A. The inhibitor may be an antibody, an siRNA molecule, an antisense molecule, or a ribozyme.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascu lar endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.

Abstract: Provided are methods of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. Also provided are antibodies that have the amino acid sequences i) to iii), iv) to vi), or i) to vi): i) SEQ ID NO:9, ii) SEQ ID NO:10, iii) SEQ ID NO:11, iv) SEQ ID NO:13, v) SEQ ID NO:14, vi) SEQ ID NO:15. Further provided are methods of inhibiting angiogenesis in an individual in need thereof comprising administering the extracellular domain (residues 1-467) of MR, or a fragment thereof, that inhibits angiogenesis, to the individual. Methods of inhibiting endothelial cell migration and/or proliferation comprising administering the extracellular domain of MR, or a fragment thereof, that inhibits endothelial cell migration and/or proliferation are also provided.